Pancreatic enzymes and abdominal adipose tissue distribution in new-onset prediabetes/diabetes after acute pancreatitis

Figure 1 Contributions of the studied fat phenotypes to the variance in circulating levels of pancreatic amylase in the healthy controls, type 2 prediabetes/diabetes mellitus, and new-onset prediabetes/diabetes after acute pancreatitis groups. Footnote: Data are presented as a percentage of the corresponding abdominal fat phenotype that explains the variance in circulating levels of pancreatic amylase. A: New-onset prediabetes/diabetes after acute pancreatitis; B: Type 2 prediabetes/diabetes mellitus; C: Healthy controls.

Figure 2 Contributions of the studied fat phenotypes to the variance in circulating levels of pancreatic lipase in the healthy controls, type 2 prediabetes/diabetes mellitus, and new-onset prediabetes/diabetes after acute pancreatitis groups. Data are presented as a percentage of the corresponding abdominal fat phenotype that explains the variance in circulating levels of pancreatic lipase. A: New-onset prediabetes/diabetes after acute pancreatitis; B: Type 2 prediabetes/diabetes mellitus; C: Healthy controls.

Figure 3 Contributions of the studied fat phenotypes to the variance in circulating levels of chymotrypsin in the healthy controls, type 2 prediabetes/diabetes mellitus, and new-onset prediabetes/diabetes after acute pancreatitis groups. Data are presented as a percentage of the corresponding abdominal fat phenotype that explains the variance in circulating levels of chymotrypsin. A: New-onset prediabetes/diabetes after acute pancreatitis; B: Type 2 prediabetes/diabetes mellitus; C: Healthy controls.